诺瓦瓦克斯医药（Novavax）股价在盘前交易中大跌5.85%，投资者对公司COVID-19疫苗前景感到担忧。
据报道，美国食品和药物管理局（FDA）未能在最后期限前就诺瓦瓦克斯生产的COVID-19疫苗做出关键决定。这一延迟发生在FDA疫苗主管几天前被推出的背景下，引发了市场对诺瓦瓦克斯疫苗审批进程的担忧。
这一消息对诺瓦瓦克斯来说是一个重大打击，因为该公司的COVID-19疫苗是其主要产品之一。FDA决策的延迟可能会影响公司的市场策略和财务预期，导致投资者对公司短期前景产生疑虑。市场将密切关注FDA的后续行动及其对诺瓦瓦克斯业务的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.